State Ledger
Company profile

Evommune, Inc. CIK 2044725

Ticker
EVMN (NYSE)
Industry
Pharmaceutical Preparations
Headquarters
Palo Alto, CA
Fiscal year end
2025 (FY)
Market Data
Close
$6.22
Change
-$0.17
Change %
-2.66%
Volume
46,631

EVMN · trading date Oct 9, 2026 · previous close $6.39 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
$13.00M
Net income
-$68.87M
Total assets
$224.95M
Total liabilities
$19.38M
Stockholders' equity
$205.57M
Cash & equivalents
$44.06M
Operating income
-$81.07M
Operating cash flow
-$76.44M
Capital expenditures
$235.0K

Fiscal year 2025, via 10-K filed 2026-03-05. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
-623.6%
Net margin
-529.8%
Free cash flow
-$76.68M
Free cash flow margin
-589.8%
Liabilities / assets
8.6%
Equity / assets
91.4%
CapEx / revenue
1.8%
Operating cash flow / net income
1.11×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 $13.00M -$68.87M $224.95M $19.38M $205.57M
2024 $7.00M -$66.81M $76.06M $28.52M -$144.24M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-09-15
Financials filed via
Form 10-K
filed 2026-03-05

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Palo Alto, CA
1891 PAGE MILL RD
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:20 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to California — Public Companies